Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00327834 · ClinicalTrials.gov registry record · Phase 4

Atomoxetine in the Treatment of Binge Eating Disorder

A Phase 4 study of Binge-Eating Disorder, sponsored by Lindner Center of HOPE.

Completed
Registry status
Phase 4
Development phase
1
Study location

NCT00327834 is a Phase 4 study of Binge-Eating Disorder that has completed, run by Lindner Center of HOPE. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00327834, a Phase 4 study of Binge-Eating Disorder, has completed, sponsored by Lindner Center of HOPE.

COMPLETED
Registry status
Phase 4
Development phase
1
Study location

Study Summary

The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

Conditions Studied

Interventions

  • DRUG atomoxetine

Study Locations (1)

Ohio

  • University of Cincinnati Medical Center - Cincinnati

Trial Details

FieldValue
Start Date 2006-05
Est. Completion 2007-03
Phase Phase 4

Sponsor

Lindner Center of HOPE

23 total trials

What the Registry Record Tells You About NCT00327834

The ClinicalTrials.gov registry entry for NCT00327834 describes a study currently listed as completed, categorized as Phase 4. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Binge-Eating Disorder appearing as the primary indexed condition, and to 1 intervention - of which atomoxetine is the first listed.

NCT00327834 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT00327834 about?

NCT00327834 is a clinical study titled "Atomoxetine in the Treatment of Binge Eating Disorder". The specific aim of this study is to assess the efficacy and safety of atomoxetine compared with placebo in outpatients with binge eating disorder.

What is the current status of trial NCT00327834?

This trial is currently completed. It is a Phase 4 study. The study started on 2006-05. Estimated completion is 2007-03.

What conditions does trial NCT00327834 study?

This clinical trial studies the following conditions: Binge-Eating Disorder.

What interventions are being tested in trial NCT00327834?

The interventions under investigation include: atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00327834?

This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00327834 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.